Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of CM383 in Healthy Subjects
Sponsor: Keymed Biosciences Co.Ltd
Summary
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.
Official title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CM383 Following Intravenous and Subcutaneous Administration in Healthy Adult Subjects
Key Details
Gender
MALE
Age Range
18 Years - 54 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-01
Completion Date
2026-07
Last Updated
2026-01-23
Healthy Volunteers
Yes
Conditions
Interventions
CM383
CM383 subcutaneous injection, once.
CM383
CM383 intravenous infusion, once.
Locations (1)
The Second Affiliated Hospital Zhejiang University School of Medcine
Hangzhou, China